Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Hodgkin's Lymphoma: early-phase trial registry
12 of 64 indexed Non-Hodgkin's Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #215 of 28,707 conditions by registered trial count.
64 US clinical trials · 12 currently recruiting · #215 of 28,707 conditions by registered trial count
Non-Hodgkin's Lymphoma: 64 US clinical trials tracked, 12 recruiting.
Non-Hodgkin's Lymphoma is the subject of 64 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 6 of these trials.
Enrollment posture brief
Registry condition non-hodgkins-lymphoma
OPEN 12 | RECR 19% | LATE 5 | EARLY 54 | RANK #215 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Allergy (19% recruiting · 16 trials)
Non-Hodgkin's Lymphoma lists 12 open slots (19% of 64 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Hodgkin's Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Hodgkin's Lymphoma is recruiting below its size-band peers.
12 of 64 indexed trials (18.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Hodgkin's Lymphoma trials is spread across many organizations.
Baylor College of Medicine accounts for 6 of 64 trials (9.4%). 39 distinct sponsors appear on at least one study for this condition label.
-
Most Non-Hodgkin's Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 64 trials that report a genuine target (sentinel values excluded). 45 of those (70.3%) plan for fewer than 100 participants.
-
Non-Hodgkin's Lymphoma research is mostly interventional.
59 interventional and 5 observational studies make up this index (92.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
64 total, page 1 of 2
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
NCT01890486
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Stanford University
NCT02848274
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Dana-Farber Cancer Institute
NCT00131014
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Hoffmann-La Roche
NCT03075696
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme
NCT04728893
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
AbbVie
NCT06667687
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
NCT05618028
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Baylor College of Medicine
NCT01555892
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT04002947
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Ascentage Pharma Group
NCT04496349
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT05884333
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Estrella Biopharma
NCT06343311
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
NCT03844048
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT01746849
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Baylor College of Medicine
NCT00840853
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Memorial Sloan Kettering Cancer Center
NCT01269593
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Cancer Institute (NCI)
NCT03789240
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03198026
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
Baylor College of Medicine
NCT01192464
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01840566
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Baylor College of Medicine
NCT00710892
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Baylor College of Medicine
NCT02050347
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Sana Biotechnology
NCT06285422
Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
NCT00341952
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Millennium Pharmaceuticals
NCT00312845
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Teva Branded Pharmaceutical Products R&D
NCT00877006
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
NCT01592370
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
David Rizzieri, MD
NCT00597714
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT00576758
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
TG Therapeutics
NCT02006485
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
M.D. Anderson Cancer Center
NCT00352846
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
NCT02611323
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Memorial Sloan Kettering Cancer Center
NCT00582933
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
Gilead Sciences
NCT00285428
Amifostine for Head and Neck Irradiation in Lymphoma
Dana-Farber Cancer Institute
NCT00136474
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT02453087
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Cephalon
NCT01073163
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
National Cancer Institute (NCI)
NCT00001430
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
Duke University
NCT01904175
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Baylor College of Medicine
NCT00368355
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Celgene
NCT00179673
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
University of Nebraska
NCT00571493
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
University of Wisconsin, Madison
NCT01281917
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics
NCT01647971
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
University of California, San Francisco
NCT00516152
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Amgen
NCT02961881
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
NCT01408563
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Massachusetts General Hospital
NCT00133367
Meloxicam vs Placebo for Mobilization
Massachusetts General Hospital
NCT02003625
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT00144677
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 27 |
| Phase 2 | 27 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Hodgkin's Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Hodgkin's Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Hodgkin's Lymphoma page
64 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Non-Hodgkin's Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Non-Hodgkin's Lymphoma trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Hodgkin's Lymphoma condition card totals 64 registered trials; most-linked intervention Rituximab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.